Navigation Links
Ampio Pharmaceuticals Announces Registered Direct Common Stock Offering of Approximately $9.436 Million
Date:12/21/2011

tion under the securities laws of any state or jurisdiction.

About Ampio

Ampio Pharmaceuticals, Inc. develops innovative proprietary drugs for metabolic disease, eye disease, kidney disease, inflammation, CNS disease, and male sexual dysfunction. The product pipeline includes new uses for previously approved drugs and new molecular entities ("NMEs").  By concentrating on development of new uses for previously approved drugs, approval timelines, costs and risk of clinical failure are reduced because these drugs have strong potential to be safe and effective while their shorter development times can significantly increase near term value. A key strategy includes actively exploring partnership, licensing and other collaboration opportunities to maximize Ampio's product development programs. For more information about Ampio, please visit our website, www.ampiopharma.com.

Forward-Looking Statements

Ampio's statements in this press release that are not historical fact and that relate to future plans or events are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by use of words such as "believe," "expect," "plan," "anticipate," and similar expressions. These forward-looking statements include risks associated with clinical trials, expected results, regulatory approvals, and changes in business conditions and similar events. The risks and uncertainties involved include, but are not limited to, statements relating to Ampio's ability to successfully complete the proposed offering and the use of proceeds therefrom, as well as other risks that are described in further detail in the preliminary prospectus supplement relating to the offering and in Ampio's filings with the Securities and Exchange Commission, including Ampio's Annual Report on Form 10-K and Quarterly Reports on Form 10-
'/>"/>

SOURCE Ampio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Ampio Responds to Recent Publications by Anonymous Short Sellers
2. Champions Oncology Reports Fiscal 2012 Second Quarter Financial Results
3. FDA Advisory Panel Recommends Against Approval of Champion® Heart Failure Management System for Patients With Heart Failure
4. Ampio Pharmaceuticals Awarded European Patent that Strengthens Intellectual Property Protection for its key drug Ampion™
5. Ampio Pharmaceuticals Announces Agreement to Acquire Key Drug Delivery Technology
6. Ampio Pharmaceuticals Expands Patent Portfolio of Drugs for Treating Inflammatory Diseases
7. Ampio Pharmaceuticals Announces Positive Results on Ampion™ Trial for Relief of Nasal Inflammation
8. Champions Oncology, Inc. Appoints Executive Vice President and Chief Financial Officer to Management Team and Corporate Office Relocation
9. Ampio Pharmaceuticals Announces a Proof of Concept Trial of Danazol in the Treatment of Allergic Rhinitis Supports Mechanism of Action of Optina™
10. Ampio Pharmaceuticals Receives Notice of Allowance of its Two Patent Applications on the Combination of Zertane™ with Erectile Dysfunction Drugs in Canada
11. Ampio Announces Positive Results From 12-Week Open Label Extension Study of Zertane™ in Patients With Premature Ejaculation.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... AMBOY, N.J. , Sept. 29, 2014 ... accept customer service inquiries via Twitter, the social media ... to Tweet inquiries and issues related to customer service ... Twitter,s ubiquitous use and its accessibility from any ... Medical Center to better serve its patients and community. ...
(Date:9/29/2014)... , Sept. 29, 2014 Tianyin ... ), a pharmaceutical company that specializes in patented ... and active pharmaceutical ingredients (API), today announced that ... official site visit by the China Food & ... (GMP) certification. In early September 2014, ...
(Date:9/29/2014)... Sept. 29, 2014  Diplomat, the nation,s largest ... has been named chief information officer. As ... the information technology department while being responsible for ... and external partnerships. Prior to joining ... in the development of technology architectures and organizational ...
Breaking Medicine Technology:@myrbmc: Healthcare Customer Service Support in 140 Characters or Less 2TPI's QLF Completes GMP site inspection by CFDA 2TPI's QLF Completes GMP site inspection by CFDA 3Diplomat names Stephen S. Brown chief information officer 2
... Dec. 6, 2011  Therakos, Inc., a pioneer in ... immune modulation therapy, today announced that the first ... clinical study evaluating the use of the company,s ... moderate-to-severe chronic Graft-versus-Host Disease (GvHD). An estimated 15,000 ...
... Dec. 6, 2011 Mobile patient monitoring innovator ... to collaborate with Qualcomm Life Inc., a wholly ... execute a home health monitoring initiative that integrates ... Qualcomm 2net™Platform. The initial focus of AirStrip,s initiative ...
Cached Medicine Technology:First Patient Enrolled in Therakos Phase Two Study for Treatment of Graft-versus-Host Disease 2First Patient Enrolled in Therakos Phase Two Study for Treatment of Graft-versus-Host Disease 3AirStrip Technologies Announces Home Health Collaboration With Qualcomm Life 2AirStrip Technologies Announces Home Health Collaboration With Qualcomm Life 3
(Date:9/30/2014)... New York, NY (PRWEB) September 30, 2014 ... an award-winning managed IT solutions firm based in ... contract to deploy CRA’s Manage360° solution to transform, ... NYC-based Nonprofit Organization (NPO) who is a leading ... become healthy, productive, and self sufficient. The ...
(Date:9/30/2014)... 2014 All on Four dental ... persons who have received dental implants to vigilant in ... post. , The post, which can be found at ... if they don’t brush and floss diligently, they could ... their natural teeth: the bone will deteriorate and the ...
(Date:9/30/2014)... September 30, 2014 Signet Puerto ... based in San Juan, Puerto Rico, leverages RamSoft’s ... , Nivia Souffront, site Administrator for Signet ... “We are excited to bring in PowerServer RIS/PACS/PM ... patient care and physician satisfaction while reducing our ...
(Date:9/30/2014)... Westminster, Maryland (PRWEB) September 30, 2014 3M ... of acrylic very high bond tapes. 3M 5906 , ... 3M 5909 are conformable VHBs which help create the ... acrylic foam tapes are used for bonding to difficult surfaces ... , 3M VHBs 5906, 5907, 5908, and 5905 are designed ...
(Date:9/30/2014)... Doctors often order breast ultrasounds as a follow-up, after a ... are done at a specialized medical imaging center, such as ... The Center for Diagnostic Imaging is now offering breast ultrasounds ... find ultrasounds to be more comfortable as they can be ... perfectly still. , “We realize that receiving abnormal ...
Breaking Medicine News(10 mins):Health News:CRA Awarded Managed Services Contract for Large NYC Nonprofit 2Health News:All on Four Dental Implants Dentist Writes Blog on Preventing Gum Disease 2Health News:All on Four Dental Implants Dentist Writes Blog on Preventing Gum Disease 3Health News:Signet Puerto Rico Leverages PowerServer RIS/PACS/PM™ to Improve Patient Care, Cut Costs 2Health News:3M Releases New VHB™ Thin Foam Tapes as the Ultimate Electronics Bonding Solution 2Health News:3M Releases New VHB™ Thin Foam Tapes as the Ultimate Electronics Bonding Solution 3Health News:Breast Ultrasounds Are a Comfortable and Convenient Option for Patients and Referring Doctors 2
... bacteria, scientists had been able to use light as ... cavity. ,The dental samples obtained from patients suffering ... to 520nm). The light had selectively killed oral black-pigmented ... samples obtained from patients. Medium strength light had killed ...
... team from the University of Western Ontario had found out that ... ,The study used a robot arm to show how ... the video of this learning process was shown to a group, ... the people in the video. Moreover people who learned the same ...
... scientists, consuming food with high glycemic index have been //linked ... which had spanned 16.6 years and observed the incidence of ... is much significant for women who are past their menopause. ... foods that have simple carbohydrates and sugars like refined flour, ...
... can lead to mothers being less emotionally involved with ... a new study done by researchers of Pennsylvania State ... pregnancy and childbirth was previously related to post-partum depression ... The new study suggests that bonding with their newborns ...
... the second phase of testing of the vaccine for ... cancers and 90% of genital warts. ,277 women ... months and regularly had gynecological examination, cervicovaginal sampling for ... to HPV. , ,The results showed the incidence ...
... the pattern of rising early from bed in the mornings ... ,The behavior is called familial advanced sleep phase ... is said to be the phenotype of the gene PER2. ... the phosphorylation site in the casein kinase I (CKI) domain ...
Cached Medicine News:
... Micro Anchor is the smallest, strongest ... flexibility in placement into even the ... with 3-0 or 4-0 ETHIBOND EXCEL ... or cutting swaged needles. The kit ...
... a threaded titanium anchor, specifically ... The anchor features wide threads ... optimize bone purchase, as well ... prevent suture binding. Fastin RC ...
The GII titanium anchor is the "Gold Standard" for soft tissue reattachment to bone. The GII's small size, high pull-out strength and wide range of clinical applications make it the anchor of choice ...
... Proxis features 'proximal protection' -- providing ... removal, even in vessels with side branches. ... to use. It does not require the ... removal of embolic debris. ,Proxis is ...
Medicine Products: